AskBorsa
ARSign up free
Companies·Minapharm Pharmaceuticals·MIPH

Minapharm Pharmaceuticals results, Q2 2026

Net profit, assets, equity and cash flow for Q2 2026, against the same period a year earlier, from the published financial statements. Consolidated figures cover the 6 months to 30 June 2026; the comparison is with the same months a year earlier, from the same disclosure.

Net profit108 millionEGP · +151.3% vs the same period a year earlier
Total assets14.24 billionEGP · +8.3% vs the same period a year earlier
Shareholders' equity6.5 billionEGP · +2.2% vs the same period a year earlier
Operating cash flow-565 millionEGP · −380.3% vs the same period a year earlier

In short

  • Minapharm Pharmaceuticals's net profit for Q2 2026 was about 108 million EGP, up +151.3% from -212 million EGP in Q2 2025.
  • Total assets at the end of Q2 2026 were about 14.24 billion EGP, and shareholders' equity about 6.5 billion EGP.
  • Operating cash flow for Q2 2026 was negative at 565 million EGP.
Source: the Q2 2026 financial statements, read from the published report

Key lines against the same period a year earlier

This periodQ2 2025Change
Net profit108 million-212 million+151.3%
Gross profit1.29 billion1.28 billion+1.1%
Total assets14.24 billion13.15 billion+8.3%
Total liabilities7.74 billion6.79 billion+14.0%
Shareholders' equity6.5 billion6.36 billion+2.2%
Operating cash flow-565 million202 million−380.3%

Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Consolidated figures cover the 6 months to 30 June 2026; the comparison is with the same months a year earlier, from the same disclosure.

Official report (PDF)All of Minapharm Pharmaceuticals's statements, five yearsAsk the AI analyst about MIPH

Minapharm Pharmaceuticals's Q3 2026 results, the day they are published

One email on the day, no account, and a one-click stop in the email itself.

orFollow on TelegramEvery result as it lands, in the @askborsa channel

By subscribing you agree to receive these alerts only. Privacy policy

Other periods for Minapharm Pharmaceuticals

Q2 2025Q2 2024Q2 2023Q2 2022Q2 2021Q1 2026Every company's results for Q2 2026